ALMS vs. AMPH, APGE, NTLA, VRNA, BHC, VERA, MIRM, HRMY, ZLAB, and GLPG
Should you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Amphastar Pharmaceuticals (AMPH), Apogee Therapeutics (APGE), Intellia Therapeutics (NTLA), Verona Pharma (VRNA), Bausch Health Companies (BHC), Vera Therapeutics (VERA), Mirum Pharmaceuticals (MIRM), Harmony Biosciences (HRMY), Zai Lab (ZLAB), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry.
Alumis (NASDAQ:ALMS) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.
65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Alumis currently has a consensus target price of $27.50, suggesting a potential upside of 129.93%. Amphastar Pharmaceuticals has a consensus target price of $63.00, suggesting a potential upside of 38.83%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Amphastar Pharmaceuticals.
In the previous week, Amphastar Pharmaceuticals had 9 more articles in the media than Alumis. MarketBeat recorded 11 mentions for Amphastar Pharmaceuticals and 2 mentions for Alumis. Amphastar Pharmaceuticals' average media sentiment score of 1.03 beat Alumis' score of 0.35 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.
Amphastar Pharmaceuticals has a net margin of 23.36% compared to Alumis' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 29.79% beat Alumis' return on equity.
Amphastar Pharmaceuticals has higher revenue and earnings than Alumis.
Amphastar Pharmaceuticals received 384 more outperform votes than Alumis when rated by MarketBeat users. However, 100.00% of users gave Alumis an outperform vote while only 66.55% of users gave Amphastar Pharmaceuticals an outperform vote.
Summary
Amphastar Pharmaceuticals beats Alumis on 9 of the 14 factors compared between the two stocks.
Get Alumis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
